[go: up one dir, main page]

PE20051170A1 - DERIVADOS DE PIRROL COMO INHIBIDORES DEL FACTOR Xa - Google Patents

DERIVADOS DE PIRROL COMO INHIBIDORES DEL FACTOR Xa

Info

Publication number
PE20051170A1
PE20051170A1 PE2005000176A PE2005000176A PE20051170A1 PE 20051170 A1 PE20051170 A1 PE 20051170A1 PE 2005000176 A PE2005000176 A PE 2005000176A PE 2005000176 A PE2005000176 A PE 2005000176A PE 20051170 A1 PE20051170 A1 PE 20051170A1
Authority
PE
Peru
Prior art keywords
alkyl
compounds
factor
group
thiofen
Prior art date
Application number
PE2005000176A
Other languages
English (en)
Inventor
Armin Bauer
Michael Wagner
Marc Nazare
Vollkmar Wehner
Matthias Urmann
Hans Matter
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20051170A1 publication Critical patent/PE20051170A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) Y (Ia); EN DONDE R0 ES UN ARILO MONO O BICICLICO, TALES COMO FENILO, PIRIDILO, HETEROCICLILO DEL GRUPO DE TIENILO, TIADIAZOLILO, ISOXAZOLILO, ENTRE, OPCIONALMENTE MONO, DI O TRISUSTITUIDOS POR R8; DONDE R8 ES HALOGENO, -O-ALQUILO(C1-C4)-, -O-CF3, ENTRE OTROS; R1 ES H, ALQUILO(C1-C2), ENTRE OTROS; Q ES -C(O), -C(O)-METILENO, -ALQUILENO(C1-C4), ALQUILENO(C0-C2)-C(O)-NR10, ENTRE OTROS; R1-N-V PUEDE FORMAR UN GRUPO CICLICO DE 4 A 8 MIEMBROS COMO AZETIDINA, PIRROLIDINA, PIPERIDINA O PIPERAZINA, ENTRE OTROS; V ES HETEROCICLILO DEL GRUPO QUE CONTIENE LOS COMPUESTOS DERIVADOS DE AZAINDOLILO (1H-PIRROLOPIRIDILO), AZETIDINA, 1,4-DIAZEPANO, ENTRE OTROS; G ES UN ENLACE DIRECTO, (CH2)m-, -(CH2)m-NR10; M ES H, ALQUILO(C1-C6), HETEROCICLILO, ENTE OTROS; R3, R4 Y R22 SON INDEPENDIENTEMENTE, H, HALOGENO, ALQUILO(C1-C4), PERFLUOROALQUILO(C1-C3), FENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (1-ISOPROPIL-PIPERIDIN-4-IL)-AMIDA DEL ACIDO 1-[5-(5-CLORO-TIOFEN-2-IL)ISOXAZOL-3-ILMETIL]-1H-PIRROL-2-CARBOXILICO, ESTER BENCILICO DEL ACIDO 1-[(5-(5-CLORO-TIOFEN-2-IL)-ISOXAZOL-3-ILMETIL]-4-(1-ISOPROPIL-PIPERIDIN-4-ILCARBAMOIL)-1H-PIRROL-2-CARBOXILICO. TAMBIEN SE REFIERE A UN PROCESO DE ELABORACION Y UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES REVERSIBLES DEL FACTOR Xa (FXa) Y/O FACTOR VIIa (FVIIa) DE LAS ENZIMAS DE COAGULACION DE LA SANGRE, POR LO QUE PRESENTAN UN EFECTO ANTITROMBOTICO Y SON ADECUADOS EN TRANSTORNOS CARDIOVASCULARES
PE2005000176A 2004-02-27 2005-02-15 DERIVADOS DE PIRROL COMO INHIBIDORES DEL FACTOR Xa PE20051170A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04004503A EP1568698A1 (en) 2004-02-27 2004-02-27 Pyrrole-derivatives as factor Xa inhibitors

Publications (1)

Publication Number Publication Date
PE20051170A1 true PE20051170A1 (es) 2006-02-07

Family

ID=34745922

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000176A PE20051170A1 (es) 2004-02-27 2005-02-15 DERIVADOS DE PIRROL COMO INHIBIDORES DEL FACTOR Xa

Country Status (13)

Country Link
US (1) US7465806B2 (es)
EP (2) EP1568698A1 (es)
JP (1) JP4861306B2 (es)
KR (1) KR20070000487A (es)
CN (1) CN1926137A (es)
AU (1) AU2005219507A1 (es)
BR (1) BRPI0508048A (es)
CA (1) CA2557270A1 (es)
IL (1) IL177253A0 (es)
PE (1) PE20051170A1 (es)
TW (1) TW200538110A (es)
UY (1) UY28778A1 (es)
WO (1) WO2005085239A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358268B2 (en) * 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
EP1571154A1 (en) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors
TW200840815A (en) * 2007-04-13 2008-10-16 Chang Chun Plastics Co Ltd Method for preparing melamine salt of bis(pentaerythritol phosphate)phosphoric acid
WO2008149382A1 (en) * 2007-06-08 2008-12-11 Advinus Therapeutics Private Limited Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX358640B (es) 2008-01-04 2018-08-29 Intellikine Llc Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
WO2010137017A2 (en) 2009-05-27 2010-12-02 Yeda Research And Development Co. Ltd. Proteasome inhibitors and uses thereof
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN105102000B (zh) 2012-11-01 2021-10-22 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
HRP20201131T1 (hr) 2016-05-31 2020-10-30 Kalvista Pharmaceuticals Limited Derivati pirazola kao inhibitori kalikreina plazme
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
DK3716952T3 (da) 2017-11-29 2022-03-14 Kalvista Pharmaceuticals Ltd Doseringsformer omfattende en plasmakallikrein-inhibitor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN113192004B (zh) * 2021-04-01 2022-01-18 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 一种基于冠脉多模影像裂纹形成和扩展的简化计算方法与斑块破裂风险量化的评估系统
WO2025024685A2 (en) * 2023-07-27 2025-01-30 Thomas Jefferson University Inhibitors of cib1 interactions and methods of use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA873607B (en) * 1986-06-13 1988-12-28 Warner Lambert Co N-1h-tetrazol-5-yl-2-thiophene carboxamides,n-1h-tetrazol-5-yl-2-pyrrole carboxamides n-1h-tetrazol-5-yl-2-furan carboxamides
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
CA2186497C (en) 1994-04-26 2008-06-17 Fahad Al-Obeidi Factor xa inhibitors
IT1282797B1 (it) * 1995-04-21 1998-03-31 Colla Paolo Pirril-(indolil)-aril-sulfoni e relativo processo di produzione ed impiego nella terapia delle infezioni da virus dell'aids
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
EP0946508B1 (en) * 1996-12-23 2009-09-23 Bristol-Myers Squibb Pharma Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
JP2001526268A (ja) * 1997-12-22 2001-12-18 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤としての、オルト−置換Ｐ１を有する、窒素含有複素環式芳香族化合物
ES2241194T3 (es) * 1997-12-24 2005-10-16 Aventis Pharma Deutschland Gmbh Derivados de indol en calidad de inhibidores de factor xa.
NZ507760A (en) * 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
CN1230421C (zh) * 1999-02-10 2005-12-07 三菱制药株式会社 酰胺化合物及其药物用途
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
AU2001273040A1 (en) * 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002020620A2 (en) 2000-09-05 2002-03-14 Medical Research Council Monoclonal antibody against ovarian carcinoma
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2002053157A1 (en) * 2000-12-30 2002-07-11 Geron Corporation Thiazolidine derivative
WO2002053155A1 (en) * 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
MY136316A (en) * 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
DE60333762D1 (de) * 2002-08-23 2010-09-23 Novartis Vaccines & Diagnostic Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
WO2004039318A2 (en) * 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
US7358268B2 (en) * 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
KR100704097B1 (ko) * 2003-01-02 2007-04-06 에프. 호프만-라 로슈 아게 신규 ｃｂ 1 수용체 역작용제
US7741341B2 (en) * 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7317027B2 (en) * 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1571154A1 (en) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors

Also Published As

Publication number Publication date
CN1926137A (zh) 2007-03-07
EP1568698A1 (en) 2005-08-31
UY28778A1 (es) 2005-09-30
TW200538110A (en) 2005-12-01
IL177253A0 (en) 2006-12-10
JP2007523927A (ja) 2007-08-23
WO2005085239A3 (en) 2005-10-13
AU2005219507A1 (en) 2005-09-15
US7465806B2 (en) 2008-12-16
KR20070000487A (ko) 2007-01-02
JP4861306B2 (ja) 2012-01-25
WO2005085239A2 (en) 2005-09-15
EP1725550A2 (en) 2006-11-29
US20070049573A1 (en) 2007-03-01
CA2557270A1 (en) 2005-09-15
BRPI0508048A (pt) 2007-07-17

Similar Documents

Publication Publication Date Title
PE20051170A1 (es) DERIVADOS DE PIRROL COMO INHIBIDORES DEL FACTOR Xa
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
PE20091429A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne)
ECSP066414A (es) Derivados de malonamida que bloquean la actividad de gama-secretasa
JP2010530391A (ja) 置換オキサゾリジノン類およびそれらの使用
PE20040864A1 (es) Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
PE20071009A1 (es) Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3
PE20080702A1 (es) PROLINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20080281A1 (es) COMPUESTOS CINAMIDA COMO INHIBIDORES DE LA SINTESIS DEL ß-AMILOIDE 40 Y 42
ME02648B (me) Jedinjenje pirazin karboksamida
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
AR069480A1 (es) Derivados de 2-amino-pirimidina
PE20060427A1 (es) Derivados de pirazol como inhibidores de la union del glucagon y composiciones
AR041298A1 (es) Derivados de pirrolidona como inhibidores de maob
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
AU2012200212A8 (en) Novel pyrrolidine-3,4-dicarboxamide derivatives
PE20050732A1 (es) Antibioticos de oxazolidinona sustituidos con un grupo ciclopropilo y derivados de los mismos
PE20050924A1 (es) Compuestos de tiazolidinonas como inhibidores de quinasa tipo polo (plk)
PE20050310A1 (es) Derivados del acido 3-(1-[3-(1,3--benzotiazol-6-il)propilcarbamoil]cicloalquil)propanoico como inhibidores de nep
PE20030661A1 (es) N-[4-(1H-IMIDAZOL-1IL)-2-FLUOROFENIL]-3-(TRIFLUOROMETIL)-1H-PIRAZOL-5-CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
BR0312586A (pt) Derivados de pirolidina como antagonistas e oxitocina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal